期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

IL-6单克隆抗体在类风湿关节炎中的应用 被引量：1

下载PDF
导出
摘要 类风湿性关节炎（RA）是一种慢性的炎症性疾病，主要以持续的关节炎症、系统性炎症和免疫异常为临床病理生理特征。细胞因子TNF-α和IL-6在RA发展过程中发挥着重要的作用，所以它们可作为治疗RA新的靶点。TNF抑制剂与IL-6抑制剂TCZ在目前治疗RA中占据重要的地位。本综述主要总结了近期在临床中对TCZ进行的试验研究以及其与TNF抑制剂在疗效、副作用等反面的对比研究。由于生物制剂较为突出的疗效，目前治疗RA的策略已经发生转移。因为RA是一种复杂的异质性疾病，TNF-α以及IL-6在其病理机制中可能共同发挥作用，所以如何选择最佳的治疗RA的方案可能还需要进一步的研究。
作者 邓晓威
机构地区 黑龙江中医药大学附属第一医院
出处 《中国伤残医学》 2014年第14期321-323,共3页 Chinese Journal of Trauma and Disability Medicine
关键词 白介素-6 类风湿性关节炎 肿瘤坏死因子
分类号 R593.21 [医药卫生—内科学]
  • 相关文献

参考文献20

  • 1Mclnnes, I.B. and G. Schett, The pathogenesis of rheumatoidrthritis. N Engl J Med, 2011. 365(23): p. 2205-19.
  • 2Jones, G. et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis, 2010. 69(1): p. 88-96.
  • 3Nishimoto, N., et al., Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumah. Ann Rheum Dis, 2007. 66(9): p. 1162-7.
  • 4Nishimoto, N., et al., Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate ( SATORI ) : significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol, 2009. 19(1): p. 12-9.
  • 5Smolen, J.S., et al., Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet, 2008. 371(9617): p. 987-97.
  • 6Genovese, M.C., et al., Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum, 2008. 58(10): p. 2968-80.
  • 7Emery, P., et al., IL-6 receptor inhibition with tocilizumab impro - yes treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis, 2008.67(11): p. 1516-23.
  • 8Kremer, J.M., et al., Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheu - m, 2011.63(3): p. 609-21.
  • 9Emery, P. A. Sebba, and T.W. Huizinga , Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis, 2013.72(12): p. 1897-904.
  • 10Dougados, M. et al. Adding tocilizumab or switching to tocilizu- mab monotherapy in methotrexate inadequate responders:24- week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). AnnRheum Dis, 2013.72(1): p. 43-0.

同被引文献21

  • 1李文珠,李迎,罗芳洪,胡庆中,陶惠然,王生育,陈彩霞,庄国洪.诱骗受体DcR3对佐剂型关节炎大鼠模型的作用分析[J].免疫学杂志,2008,24(1):23-28. 被引量：9
  • 2WELLES WL, BATLISTO JR.Suppression of adjuvant arthritis by anti- bodies specific for collagen type I1 [J].Immunol Commun, 1981,10(8) : 673-685. Y.
  • 3UDOH K, MATSUNO H, NAKAZAWA F, et al. Reduced expression of the regulatory CD4+ T cell subset is related to Thl/Th2 balance and disease severity in rheumatoid arthritis[J]. Arthritis Rheum, 2000, 43 (3):617-627.
  • 4ISHIHARA K,SAWA S,IKUSHIMA H,et al.The point mutation of ty- rosine 759 of the IL-6 family cytokine recepto gpl30 synergizes with HTLV-lpX in promoting rehumatoid arthritis-like arthritis [J].Int lm- munol, 2004, 16(3 ) : 455-465.
  • 5CHOY E.Clinical experience with inhibition of interleukin-6 [J]. Rheum Dis Clin North Am,2004,30(2):405-415.
  • 6陆扬光,余志辉,王晓娟等.Th17细胞相关细胞因子在类风湿性关节炎发病中的临床意义[J].医药前沿,2014(20):48-49.
  • 7KREMER JM,BLANCO R,BRZOSKO M,et al. Tocilizumab inhibits structuraljoint damage in rheumatoid arthritis patients with inadequate responses tomethotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial oftocilizumab safety and prevention of structural joint damage at one year [J].Arthritis Rheum, 2011,63 ( 3 ): 609-621.
  • 8GARNERO PI, THOMPSON E, WOODWORTH T, et al. Rapid and sustained improvement in bone and cartilage turnovermarkers with the anti nterleukin-6 receptorinhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response tomethotrexat results from a substudy of the muhicenter double-blind, placebo-con- trolled trial of tocilizumab ininadequate responders to methotrexate aloue[J].Arthritis Rheum, 2010,62( 1 ):33-44.
  • 9WHALEN JD, LECHMAN EL, CARRLOS CA, et al.Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws sup- presses development of collagen-induced arthritis in both injected and uninjected paws [J]. J Immunol, 1999,162(6):3625-3632.
  • 10JOOSTEN LA, LUBBERTS E, DUREZ P, et al. Role of interleukin- 4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage de- struetion.[J].Arthritis Rheum, 1997, 40(2): 249-260.

引证文献1

二级引证文献1

中国伤残医学
2014年 第14期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部